European Association of Urology
Guidelines
Education & Events
Join our events Join our events
On-demand education Learn at your own pace
Scholarships Enrich your capabilities
Exchange Programmes Urology beyond Europe
Education Educational Platforms Talent Incubator Programme Accreditation
Science & Publications
Publications Our publications
Research & Science Passionate about research?
About
Who we are Our mission and history
Our Board and Offices How we work
Join the EAU Find out about membership
Vacancies Contact

EAU15: Issues in Benign Prostatic Obstruction

Mon, 23 Mar 2015

A part of Plenary Session 3 at the 30th Anniversary Congress tackled issues in Benign Prostatic Obstruction (BPO) with speakers discussing combinedmedical treatments, optimizing transurethral resection of the prostate (TURP) and the role of lasers and alternative minimal invasive technologies.

In his presentation “Optimizing TURP,” Aurelien Descazeaud (FR) said laser devices posed a challenge to TURP, but the latter procedure remains a gold standard.

“Regarding literature and guidelines, TURP remains the gold standard for the ‘average BPH case’,” said Descazeaud, as he noted that a key issue is how to further reduce complications to maintain the role of TURP as a frontline procedure.

He added TURP has no specific learning curve and additional costs are lower compared to laser procedures. Minimising morbidities and improving functional outcomes should be the goal of urologists, according to Descazeaud, whilst noting thebipolar technique offers significant advantages over monopolar TURP.

Meanwhile, Prof. Jean De la Rosette (FR) assessed the range of laser technologies and said HoLEPhas a better perioperative profile. “There is less hemorrhage, lower transfusion rates and the procedure provides shorter catherisation and hospital stay for the patient; and also shorter operative time.”

Regarding alternative minimal invasive techniques, M. Michel (DE) gave an assessment of these procedures. He said prostatic arterial embolization (PAE) and prostatic urethral lift (PUL) are both “ready to prove their value in daily and evidence-based medicine.” The same, however, cannot be said for botox and ethanol injections which he considers obsolete and hardly have any therapeutic value.

On PRX 302, which is highly targeted to prostate tissue and delivered directly to the encapsulated prostate via localized injection, Michel said the procedure shows good functional outcome with promising results being awaited.

Share this article

About EAU
  • Who we are
  • How we work
  • Become a member
Services
  • MyEAU
  • Congress registrations
  • Abstract submission
Media
  • EAU News
  • EAU Newsletter
  • EAU Press Releases
Contact
  • EAU Central Office
    PO Box 30016
    NL-6803 AA ARNHEM
    The Netherlands

  • Contact us
About EAU
Who we areHow we workBecome a member
Services
MyEAUCongress registrationsAbstract submission
Media
EAU NewsEAU NewsletterEAU Press Releases
Contact

EAU Central Office
PO Box 30016
NL-6803 AA ARNHEM
The Netherlands

Contact us
European Association of Urology
Privacy PolicyDisclaimer